Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 3, 2003, Pages 228-234

  Bastide, C ^a   Maroc, N ^a   Bladou, F ^b   Hassoun, J ^a   Maitland, N ^c   Mannoni, P ^d   Bagnis, Claude ^d  

^a INSTITUT PAOLI CALMETTES   (France)

^b Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^c UNIVERSITY OF YORK   (United Kingdom)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

EGPF; Gene therapy; Lentiviral vector

Indexed keywords

GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL POPULATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC ANALYSIS; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROVIRUS; SCID MOUSE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, REPORTER; HUMANS; LENTIVIRUS; MALE; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 0141725675     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500668     Document Type: Article

References (23)

1. Boring CC et al. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7-26.
2. Pound CR et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
3. Shipley WU et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 1598-1604.
4. Huggins C et al. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972; 22: 232-240.
5. Maitland NJ. Targeting therapeutic gene expression to human prostate cancers. Curr Opin Mol Ther 2000; 2: 389-399.
6. Steiner MS et al. Gene therapy for prostate cancer: where are we now? J Urol 2000; 164: 1121-1136.
7. Lu Y et al. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 1999; 6: 64-72.
8. Young LS et al. The promise and potential hazards of adenovirus gene therapy. Gut 2001; 48: 733-736.
9. Yu D et al. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8: 628-635.
10. Vigna E et al. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308-316.
11. Bagnis C et al. Viral vectors and gene markers: tools and challenges for scientists working blind on genetic modification of hematopoietic cells. In: Pandalai SG (ed). Recent Research Developments in Virology, Vol. 1. Transworld Research Network, Trivandrum, 1999, pp 217-228; Recent Res Dev Virol 1999; 1: 217-228.
12. Bastide C et al. A Nod Scid mouse model to study human prostate cancer. Prostate Cancer Prostatic Dis 2002; 5: 311-315.
13. Zufferey R et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
14. Gerolami R et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther 2000; 7: 1286-1292.
15. Sastry L et al. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Therapy 2002; 9: 1155-1162.
16. Di Ianni M et al. 5-Azacytidine prevents transgene methylation in vivo. Gene Therapy 1999; 6: 703-707.
17. Kandel ES et al. Template switching by RNA polymerase II in vivo. Evidence and implications from a retroviral system. Mol Cell Biol 2002; 10: 1495-1502.
18. Halvas EK et al. Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity. J Virol 2000; 74: 10349-10358.
19. Mizutani T et al. Maintenance of integrated proviral gene expression requires Brm, a catalytic subunit of SWI/SNF complex. J Biol Chem 2002; 277: 15859-15864.
20. Hanazono Y et al. Green fluorescent protein retroviral vectors: low liter and high recombination frequency suggest a selective disadvantage. Hum Gene Ther 1997; 8: 1313-1319.
21. Coleman JE et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-228.
22. Horig H et al. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther 2002; 2: 395-408.
23. Heiser A et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409-417.